FSD Pharma Inc Class B (HUGE) Stock

DelistedNasdaq: HUGEFSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.

5.39
Final close · Oct 16, 2024

HUGE is no longer traded. FSD Pharma Inc Class B was delisted from the Nasdaq in October 2024.

Prices on this page are historical; the last trade was October 16, 2024 at $5.39.

FSD Pharma Inc Class B stock price history

Split-adjusted closes, 2018–2024

HUGE final trading statistics

Final close
$5.39
Final trading day
Oct 16, 2024
Market cap at delisting
$66.7K
Shares outstanding
0.71M
Final 52-week range
$0.07 – $5.45
Avg. volume (final 3 mo.)
252,652
All-time high (split-adj.)
$9080.40 · Sep 2018
All-time low (split-adj.)
$3.62 · Sep 2024
Return since IPO
-99.5%
Beta
0.85
Book value / share
$17.09
Price / book
0.32
Final 52 wk
0.075.45

FSD Pharma Inc Class B earnings per share

Earnings per share

FSD Pharma Inc Class B revenue & net income

RevenueNet income

FSD Pharma Inc Class B annual financials

Fiscal yearRevenueNet incomeEPS
FY2023$0.00-$18.6M-$0.48
FY2022$0.00-$23.3M-$1.33
FY2021$0.00-$35.4M—
FY2020$196.8K-$32.7M-$3.52
FY2019$196.8K-$40.1M-$6.83

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About FSD Pharma Inc Class B

FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.

FSD Pharma Inc Class B stock FAQ

What happened to FSD Pharma Inc Class B stock?

FSD Pharma Inc Class B stock was delisted from the Nasdaq. Its final close was $5.39 on October 16, 2024.

Is HUGE stock still trading?

No. HUGE was delisted from the Nasdaq in October 2024 and no longer trades on a U.S. exchange.

What was the last price of HUGE stock?

HUGE closed at $5.39 on its final trading day, October 16, 2024, for a market value of about $66.7K.

What were FSD Pharma Inc Class B's revenue and earnings in its last full fiscal year?

FSD Pharma Inc Class B reported revenue of $0.00 and net income of -$18.6M in fiscal 2023, its last full year as a public company.

When did FSD Pharma Inc Class B go public?

FSD Pharma Inc Class B stock began trading on June 8, 2018.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →